Navigation Links
Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
Date:8/19/2007

Combination of Intracranial and Extracranial Resources Benefits Baltimore

Area and Beyond

ATLANTA and BALTIMORE, Aug. 17 /PRNewswire/ -- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medicine is adding an Elekta Synergy(R) S system to its Leksell Gamma Knife(R) capability. A Stereotactic Center of Excellence, Johns Hopkins aims to fight cancer with both intracranial and extracranial resources for whole-body cancer treatment with the addition of Elekta Synergy S this fall. Elekta Synergy S integrates high- resolution beam shaping, precise target localization, organ motion control and 3D imaging into one package, taking stereotactic radiosurgery and radiotherapy to a new level.

Theodore L. DeWeese, M.D., is Johns Hopkins professor of Radiation Oncology, Oncology and Urology and chair of the Department of Radiation Oncology and Molecular Radiation Sciences. "Elekta Synergy S is an ideal complement to Leksell Gamma Knife radiosurgery," says Dr. DeWeese. "With it, we are expanding stereotactic radiosurgery to other parts of the anatomy besides the brain."

Elekta Synergy S: advanced stereotactic radiation

Elekta Synergy S is an image-guided robotic linear accelerator that combines integrated software-driven imaging abilities with powerful high- resolution radiation delivery. At Johns Hopkins' Kimmel Center, Elekta Synergy S will enable specialists to perform both stereotactic radiosurgery and stereotactic radiotherapy throughout the body, as well as, stereotactic radiosurgery on cranial tumors unsuitable for Gamma Knife surgery.

Essentially, Elekta Synergy S provides Johns Hopkins with the two most important ingredients for improved patient outcomes: 2D and ultra low dose 3D image-guided accuracy and highly conformal beam shaping. This enables neurosurgeons at the Kimmel Center to use extremely precise stereotactic radiosurgery and stereotactic radiotherapy on small-field spinal tumors as
'/>"/>

SOURCE Elekta

Copyright©2007 PR Newswire.

Page: 1 2 3

Related biology technology :

1. Johnson Controls deals for asset-tracking software
2. Johnson Controls adds renewable energy unit
3. Johnson Controls unit lands contract for plug-in hybrid battery
4. Johnson Controls to expand in Europe
5. Johnson Controls partners on car satellite linkup
6. Florida schools employ Johnson Controls technology to stop sex predators
7. Johnson Controls partnership wins new contract
8. Johnson Controls appoints Roell to head EOC
9. Johnson Controls reports record quarterly sales
10. SC Johnson issues trademark warning over web offer
11. Research park adds Johnson Controls, Eaton
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 2015  Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage ... today announced that it will be presenting at CALBIO ... 2 nd at 3pm PST. Patrick Lucy, chief business ... the current state of the biosimilar industry landscape entitled ... For more information on CALBIO 2015 and ...
(Date:2/26/2015)... , Feb. 26, 2015 S&P Capital ... Factual Stock Report coverage on MabVax Therapeutics Holdings Inc ... is a clinical stage biotechnology company focused on the ... medical needs in the treatment of cancer. MabVax has ... on the protective immune responses generated by patients who ...
(Date:2/26/2015)... Calif. , Feb. 26, 2015   Regulus ... biopharmaceutical company leading the discovery and development of innovative ... Xanthopoulos , Ph.D., President and Chief Executive Officer of ... and Company 35 th Annual Healthcare Conference on ... conference is being held at the Boston Marriott Copley ...
(Date:2/26/2015)... , Feb. 26, 2015  NuGene International, Inc. ... products for skin and hair rejuvenation, has announced ... agency of record for investor relations and strategic ... our distribution, sales and diversification strategies – and ... and prospective shareholders," stated Ali Kharazmi CEO of ...
Breaking Biology Technology:S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 2NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 3
... Reiterates $3.00 per Share Proposal is Best and Final ... Company,(NYSE: LLY ) today reaffirmed that its $3.00 ... SGXP ) represents its best and final offer,for the ... two,companies announced the signing of a definitive merger agreement, ...
... Bionovo, Inc.,(Nasdaq: BNVI ), a pharmaceutical company focused ... in the areas of women,s health and,cancer, announced today ... presenting at the BMO Capital Markets 2008 Focus on ... begin at 2:15 PM,ET on Tuesday, August 5, 2008 ...
... to Monitor Activity of New ... Class of Potent Antiretroviral Drugs, SOUTH SAN ... ) today announced the launch of its,PhenoSense(R) Integrase assay, built ... susceptibility of,HIV to a new and potent class of integrase ...
Cached Biology Technology:Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals 2Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals 3Bionovo to Present at BMO Capital Markets 2008 Focus on Healthcare Conference 2Monogram Biosciences Launches First Resistance Assay for HIV Integrase Inhibitors 2Monogram Biosciences Launches First Resistance Assay for HIV Integrase Inhibitors 3Monogram Biosciences Launches First Resistance Assay for HIV Integrase Inhibitors 4Monogram Biosciences Launches First Resistance Assay for HIV Integrase Inhibitors 5
(Date:1/22/2015)... Report Issued by Small Cap IR. In 2011, Nilson Report,s ... at merchants on the leading payment cards rose to $135.3 ... and prepaid cards reached 6.54 billion.  Eight million credit card ... in 2012, and credit and debit card fraud resulted in ...
(Date:1/22/2015)... 22, 2015 Research and Markets ( ... "Global Wearable Technologies Market and Applications, Opportunities, ... and Forecast 2014-2020" report to their offering. ... devices that can be worn on the user,s ...
(Date:1/22/2015)... N.C. , Jan. 22, 2015 Infinisource has launched ... of the G2 model. The G2 sets a higher standard ... iSolved human capital management solution. With plug-and-play installation, touch screen ... time clock provides a robust time collection solution for the ...
Breaking Biology News(10 mins):$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2Infinisource's NXG series sets new time clock standard 2
... scientist, has just solved the structure of the first mammalian ... and certain cancers. His work is being published today ... Molecular Cell. Gewirths study confirms his 2001 ... same family as the better known HSP90 proteins. As ...
... Spring Harbor, NY Gregory J. Hannon, Ph.D., ... Hughes Medical Institute (HHMI) investigator, along with two ... the Memorial Sloan-Kettering Cancer Centers (MSKCC) 2007 Paul ... named after Paul A. Marks, Ph.D., President Emeritus ...
... researchers have shown that nanodiamonds -- much like the ... diamond but on a much smaller scale -- are ... the negative effects associated with current drug delivery agents. ... Letters, is the first to demonstrate the use of ...
Cached Biology News:First high-res 3D structures of mammalian HSP90 protein solved 2First high-res 3D structures of mammalian HSP90 protein solved 3Gregory Hannon wins 2007 Paul Marks Prize for contributions to understanding and treating cancer 2Nanoengineers mine tiny diamonds for drug delivery 2Nanoengineers mine tiny diamonds for drug delivery 3Nanoengineers mine tiny diamonds for drug delivery 4
Request Info...
Peptide-affinity Purified Polyclonal Antibody to SMAD7 Peptide with sequence SSCPCWLEVIFNSR, from C Terminus of the protein sequence according to NP_005895....
Polyclonal Antibody to PRG3...
Mouse monoclonal [2991] to C3a / C3a des Arg ( Abpromise for all tested applications). SwissProtID: P01024...
Biology Products: